Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapy

Bibliographic Details
Main Author:	WANG Deyang
Format:	Article
Language:	zho
Published:	Editorial Department of Journal of Clinical Hepatology 2021-04-01
Series:	Linchuang Gandanbing Zazhi
Online Access:	http://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.04.007

id	doaj-01385f2ed8924fb4a55441d172dc02fb
record_format	Article
spelling	doaj-01385f2ed8924fb4a55441d172dc02fb2021-04-26T08:11:45ZzhoEditorial Department of Journal of Clinical HepatologyLinchuang Gandanbing Zazhi1001-52561001-52562021-04-01374775776Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapyWANG Deyang0The Affiliated Hospital of Ningbo University School of Medicinehttp://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.04.007
collection	DOAJ
language	zho
format	Article
sources	DOAJ
author	WANG Deyang
spellingShingle	WANG Deyang Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapy Linchuang Gandanbing Zazhi
author_facet	WANG Deyang
author_sort	WANG Deyang
title	Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapy
title_short	Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapy
title_full	Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapy
title_fullStr	Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapy
title_full_unstemmed	Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapy
title_sort	patients in the immune-tolerant phase of hepatitis b virus infection benefit a lot from antiviral therapy
publisher	Editorial Department of Journal of Clinical Hepatology
series	Linchuang Gandanbing Zazhi
issn	1001-5256 1001-5256
publishDate	2021-04-01
url	http://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.04.007
work_keys_str_mv	AT wangdeyang patientsintheimmunetolerantphaseofhepatitisbvirusinfectionbenefitalotfromantiviraltherapy
_version_	1721507643980251136

Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapy

Similar Items